Soluble tumor necrosis factor receptor I (sTNFRI) as a prognostic factor in melanoma patients in Slovene population.

Autor: Galvani V; Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia, Slovenia., Hartman KP; Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia, Slovenia., Rupreht RR; Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia, Slovenia., Novaković S; Institute of Oncology, Zaloška 2, 1000 Ljubljana, Slovenia, Slovenia., Štabuc B; Institute of Oncology, Zaloška 2, 1000 Ljubljana, Slovenia, Slovenia., Ocvirk J; Institute of Oncology, Zaloška 2, 1000 Ljubljana, Slovenia, Slovenia., Menart V; Lek d.d., Celovška 135, 1000 Ljubljana, Slovenia, Slovenia., Porekar VG; National Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia, Slovenia., Štalc A; Lek d.d., Celovška 135, 1000 Ljubljana, Slovenia, Slovenia., Rožman P; Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia, Slovenia., Šerbec VČ; Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia, Slovenia.
Jazyk: angličtina
Zdroj: Pflugers Archiv : European journal of physiology [Pflugers Arch] 2000 Jan; Vol. 440 (Suppl 1), pp. R061-R063.
DOI: 10.1007/s004240000007
Abstrakt: Tumor necrosis factor α (TNF-α) and its receptors (TNFRI and TNFRII) which exist in soluble form as a product of cleavage of the extracellular domain of membrane integrated receptors, still rise debate about their importance. It was reported that TNF-α has numerous actions in diseases such as inflammation, autoimmunity, infectious diseases, septic shock and many types of cancer [1, 2]. Several authors have reported the significance of sTNFRI level in serum of cancer patients [3, 4]. This study was performed in collaboration with the Institute of Oncology of Slovenia.At least two different mouse monoclonal antibodies (MAbs) against human sTNFRI have been prepared to obtain a sensitive and reliable sandwich ELISA. It was compared with commercially available R&D and Endogen ELISAs for the determination of sTNFRI. Groups of patients with different stages of melanoma and epithelial ovarian carcinoma were tested and their clinical records were reexamined. Levels of sTNFRI were measured and compared with the normal serum levels of sTNFRI.
Databáze: MEDLINE